Synlett 2013; 24(3): 317-322
DOI: 10.1055/s-0032-1317790
cluster
© Georg Thieme Verlag Stuttgart · New York

Development of a Practical Synthesis of 4-[6-(Morpholinomethyl)-pyridin-3-yl]naphthalen-1-amine, a Key Intermediate for the Synthesis of BIRB 1017, a Potent p38 MAP Kinase Inhibitor

Bruce Z. Lu*
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Guisheng Li*
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Sonia Rodriguez
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Jianxu Liu
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Magnus C. Eriksson
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Zhulin Tan
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Jinhua J. Song
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Nathan K. Yee
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
,
Vittorio Farina*
b   Janssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium
,
Chris H. Senanayake*
a   Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368, USA   Fax: +1(203)8375283   Email: bruce.lu@boehringer-ingelheim.com   Email: guisheng.li@boehringer-ingelheim.com   Email: chris.senanayake@boehringer-ingelheim.com
› Author Affiliations
Further Information

Publication History

Received: 26 November 2012

Accepted after revision: 18 December 2012

Publication Date:
11 January 2013 (online)


Abstract

The development of synthetic routes to 4-[6-(morpholinomethyl)pyridin-3-yl]naphthalen-1-amine, the key intermediate of p38 MAP kinase inhibitor BIRB 1017, via (1) trialkylmagnesium ate complex mediated metalation and borylation followed by Suzuki coupling reactions and (2) pyridine-ring formation from a vinamidinium salt, is described.